Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. Ramalingam SS, et al. Among authors: lorusso p. J Clin Oncol. 2010 Oct 10;28(29):4507-12. doi: 10.1200/JCO.2010.30.2307. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837947 Free PMC article. Clinical Trial.
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Herbst RS, et al. J Clin Oncol. 2002 Sep 15;20(18):3815-25. doi: 10.1200/JCO.2002.03.038. J Clin Oncol. 2002. PMID: 12228201 Clinical Trial.
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB. Rinehart J, et al. Among authors: lorusso pm. J Clin Oncol. 2004 Nov 15;22(22):4456-62. doi: 10.1200/JCO.2004.01.185. Epub 2004 Oct 13. J Clin Oncol. 2004. PMID: 15483017 Clinical Trial.
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions.
Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, Ivy SP. Anderson LW, et al. Cancer Chemother Pharmacol. 2005 Oct;56(4):351-7. doi: 10.1007/s00280-004-0962-3. Epub 2005 May 13. Cancer Chemother Pharmacol. 2005. PMID: 15895233 Clinical Trial.
Phase I study of bryostatin 1 and gemcitabine.
El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. El-Rayes BF, et al. Among authors: lorusso p. Clin Cancer Res. 2006 Dec 1;12(23):7059-62. doi: 10.1158/1078-0432.CCR-06-1419. Clin Cancer Res. 2006. PMID: 17145828 Clinical Trial.
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
El-Rayes BF, Zalupski M, Shields AF, Manza SG, LoRusso P, Philip PA. El-Rayes BF, et al. Among authors: lorusso p. Am J Clin Oncol. 2007 Apr;30(2):101-5. doi: 10.1097/01.coc.0000251223.98193.f4. Am J Clin Oncol. 2007. PMID: 17414457 Clinical Trial.
421 results